Key Drivers
- Strong liquidity
- Large cash burn
- Negative margins
AIAI Summary
The $950M upfront from the Moderna settlement transforms Arbutus from a cash‑starved speculative biotech into a company with meaningful optionality and the runway to de‑risk HBV programs, but the non‑exclusive license, contingent ~$1.3B appellate payout and lingering clinical/legal execution risk mean investors should model the contingent proceeds probabilistically and watch the appellate outcome, management's capital allocation, and HBV readouts as the key catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Large cash burn
- •Negative margins
ABUS has very strong liquidity and low leverage but is suffering from persistent operating losses, heavy R&D‑driven cash burn, negative returns, and extremely high valuation multiples that together undermine its investment case.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Weak momentum
- •Repeated support tests
ABUS is slightly down in the short term (last month) trading below its ~21-day average with weak momentum (RSI ~35) and clear support at $4.25 that, if lost, would likely open the path to further downside while a sustained break above $4.70–$4.75 would be needed to restore a bullish case.
Repeated tests of $4.25 on 2026-03-18 and 2026-03-20 signal fragile near-term support
Sentiment & News
Key News Insights:
- •Cash hit
- •No royalties
- •Appeal risk
Moderna will pay $950M to settle global patent disputes with Arbutus/Genevant over Spikevax and mRESVIA, with no future royalties, a Q1 charge and revised cash guidance of $4.5–$5.0B, while a possible additional payment depends on an appeal.
The settlement removes near‑term litigation uncertainty and clears commercialization for Moderna's mRNA portfolio but reduces cash reserves and leaves contingent risk from the pending appeal
Similar Companies in Healthcare
Other companies in the same sector with AI ratings